Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $824000.0.

  • Celldex Therapeutics' Depreciation & Amortization (CF) rose 483.46% to $824000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 853.38%. This contributed to the annual value of $3.2 million for FY2024, which is 561.84% up from last year.
  • As of Q3 2025, Celldex Therapeutics' Depreciation & Amortization (CF) stood at $824000.0, which was up 483.46% from $873000.0 recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Depreciation & Amortization (CF) ranged from a high of $873000.0 in Q2 2025 and a low of $671000.0 during Q3 2022
  • In the last 5 years, Celldex Therapeutics' Depreciation & Amortization (CF) had a median value of $775000.0 in 2021 and averaged $774368.4.
  • As far as peak fluctuations go, Celldex Therapeutics' Depreciation & Amortization (CF) crashed by 3347.64% in 2021, and later surged by 1430.7% in 2023.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Depreciation & Amortization (CF) stood at $777000.0 in 2021, then dropped by 13.38% to $673000.0 in 2022, then increased by 12.78% to $759000.0 in 2023, then increased by 7.91% to $819000.0 in 2024, then increased by 0.61% to $824000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $824000.0 for Q3 2025, versus $873000.0 for Q2 2025 and $867000.0 for Q1 2025.